Public record
CJC-1295: the public record
Each table is computed from the named federal dataset as of its data date; the method is under each one.
Product listings
FDA product listings naming CJC-1295
The FDA NDC Directory holds 10 listings naming CJC-1295 from 10 firms: 10 bulk ingredient listings and 0 finished product listings, 0 under an FDA-approved application. A listing is a registration by a firm, not an FDA approval.
| Measure | Value | Note |
|---|---|---|
| Listings naming CJC-1295 | 10 | |
| Bulk ingredient listings | 10 | raw material registrations, not finished medicines |
| Of those, bulk ingredient for human prescription compounding | 4 | |
| Finished product listings | 0 | |
| Listings under an FDA-approved application | 0 | |
| Firms with a listing | 10 |
How this was calculated
Searched ingredient and product names in the NDC Directory download for the exact name variants, then counted listings by FDA marketing category and by listing firm.
Current NDC Directory listings whose ingredient or product name contains CJC-1295 or CJC 1295
Firms submit listings themselves. A listing does not mean FDA has reviewed the substance for safety or effectiveness, or that it may lawfully be compounded.
Recalls
FDA drug recalls naming CJC-1295
FDA enforcement reports list 4 drug recall entries naming CJC-1295 from 2020 to 2025-07-02. 4 of them are for compounded or other unlisted products and 0 for products FDA lists under a label. The most common stated reason was lack of sterility assurance (4 of 4).
| Measure | Value | Note |
|---|---|---|
| Recall entries on record | 4 | |
| For products FDA lists under an approved or registered label | 0 | |
| For compounded or other unlisted products | 4 | matched by the name in the product description |
| Class I (most serious) | 0 | |
| Class II | 4 | |
| Class III | 0 | |
| Most recent recall reported | 2025-07-02 | |
| Most common stated reason | lack of sterility assurance | 4 of 4 entries |
How this was calculated
Counted enforcement report entries matched by FDA's listed active substance, or by the name in the product description where FDA lists none. Reasons were grouped by keywords in FDA's stated reason.
Recalls whose product description names CJC-1295, including compounded and multi-ingredient products
Each recall covers specific lots from one firm and is not a statement about every product with this ingredient. One event can appear as several entries, one per product.
Published research
Published papers mentioning CJC-1295
PubMed indexes 35 papers that mention CJC-1295 in the title or abstract, 15 of them published from 2016 to 2025. The count for 2025 is 1 and for 2024 is 1.
| Measure | Value | Note |
|---|---|---|
| Papers indexed, all years | 35 | |
| Published 2016 to 2025 | 15 | |
| Published in 2025 | 1 | |
| Published in 2024 | 1 | |
| Busiest year since 2016 | 2022 | 3 papers |
How this was calculated
Ran a PubMed title and abstract search for the exact name variants shown and recorded the count for each publication year. No filtering by study type or quality.
PubMed records with 'CJC-1295' or 'CJC 1295' in the title or abstract, all article types and species
A paper that mentions a compound is not evidence that it works or is safe in people. Counts include animal, cell, review and opinion papers.
Articles on CJC-1295
- CJC-1295 Monitoring for Adults (30 to 49): What Studies Measured
- CJC-1295 Future Formulations & Pipeline: What's Next for This GH Secretagogue
- CJC-1295 Liver Function Impact: What the Clinical Data Actually Show
- CJC-1295 Mechanism of Action: Full Pathway From Injection to IGF-1 Output
- CJC-1295 Monitoring: What the Human Studies Measured
- CJC-1295 Off-Label Uses with Evidence Levels